Published ahead of print on August 26, 2005, doi:10.1164/rccm.200505-840OE
Am. J. Respir. Crit. Care Med., Volume 173, Number 5, March 2006, 475-482
A more recent version of this article appeared on March 1, 2006
Submitted on May 31, 2005
Accepted on August 24, 2005
Cystic Fibrosis Since 1938
Pamela B Davis*
* To whom correspondence should be addressed. E-mail: Pamela.davis{at}case.edu.
Cystic fibrosis (CF) was distinguished from celiac disease in 1938. Then, it was a pathologic diagnosis, life expectancy was ~6 months, and the autosomal recessive disease was thought to arise from abnormal mucus plugging exocrine ducts. Death often occurred from lung infection.
Discovery of the sweat electrolyte defect in 1953 and standardization of the sweat test in 1959 allowed identification of milder cases, and CF was no longer considered only a disorder of mucus. In 1955, establishment of centers with programs of aggressive, comprehensive care initiated striking improvement in longevity. The pillars of care established then (attention to nutrition, airway clearance, treatment of lung infection) remain today. In 1983, chloride transport was identified as the basic physiologic CF defect, accompanied by increased sodium reabsorption. In 1980 we learned that inflammation contributes independently to lung disease
and constitutes an independent therapeutic target. In 1989, the discovery of the CF gene demonstrated the basic defect to be in a cAMP-regulated chloride channel. This afforded new diagnostic tests, opportunities for research, and prospects for using the gene as therapy. Since
then, substantial advances in basic and clinical research catalyzed therapeutic improvements: median survival age now exceeds 30 years. The Cystic Fibrosis Foundation Center network provides not only opportunity to conduct clinical trials, but also means to disseminate new
therapies. In the future, treatments directed at the basic defect can be expected, with concomitant improvements in morbidity and mortality.
Key words: cystic fibrosis, Pseudomonas aeruginosa, sweat test
This article has been cited by other articles:

|
 |

|
 |
 
T. M. Kremer, R. G. Zwerdling, P. H. Michelson, and B. P. O'Sullivan
Intensive Care Management of the Patient With Cystic Fibrosis
J Intensive Care Med,
May 1, 2008;
23(3):
159 - 177.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Tirouvanziam, Y. Gernez, C. K. Conrad, R. B. Moss, I. Schrijver, C. E. Dunn, Z. A. Davies, L. A. Herzenberg, and L. A. Herzenberg
Profound functional and signaling changes in viable inflammatory neutrophils homing to cystic fibrosis airways
PNAS,
March 18, 2008;
105(11):
4335 - 4339.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. W. R. Serohijos, T. Hegedus, A. A. Aleksandrov, L. He, L. Cui, N. V. Dokholyan, and J. R. Riordan
Phenylalanine-508 mediates a cytoplasmic-membrane domain contact in the CFTR 3D structure crucial to assembly and channel function
PNAS,
March 4, 2008;
105(9):
3256 - 3261.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C Davies, E. W F W Alton, and A. Bush
Cystic fibrosis
BMJ,
December 15, 2007;
335(7632):
1255 - 1259.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Donadieu, C. Roudier, M. Saguintaah, C. Maccia, and R. Chiron
Estimation of the Radiation Dose From Thoracic CT Scans in a Cystic Fibrosis Population
Chest,
October 1, 2007;
132(4):
1233 - 1238.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. M. Rowe, F. Accurso, and J. P. Clancy
Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-Phase Clinical Trials
Proceedings of the ATS,
August 1, 2007;
4(4):
387 - 398.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. M. Quinton
Cystic Fibrosis: Lessons from the Sweat Gland
Physiology,
June 1, 2007;
22(3):
212 - 225.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. J. Accurso
Update in Cystic Fibrosis 2006
Am. J. Respir. Crit. Care Med.,
April 15, 2007;
175(8):
754 - 757.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. D. Wexler, M. Johannesson, F. P. Edenborough, B. S. Sufian, and E. Kerem
Pregnancy and Chronic Progressive Pulmonary Disease
Am. J. Respir. Crit. Care Med.,
February 15, 2007;
175(4):
300 - 305.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Livraghi and S. H. Randell
Cystic Fibrosis and Other Respiratory Diseases of Impaired Mucus Clearance
Toxicol Pathol,
January 1, 2007;
35(1):
116 - 129.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Roghanian, E. M. Drost, W. MacNee, S. E. M. Howie, and J.-M. Sallenave
Inflammatory Lung Secretions Inhibit Dendritic Cell Maturation and Function via Neutrophil Elastase
Am. J. Respir. Crit. Care Med.,
December 1, 2006;
174(11):
1189 - 1198.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Gayer and L. Ganong
Family structure and mothers' caregiving of children with cystic fibrosis.
Journal of Family Nursing,
November 1, 2006;
12(4):
390 - 412.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
N N Sanders, H Franckx, K De Boeck, J Haustraete, S C De Smedt, and J Demeester
Role of magnesium in the failure of rhDNase therapy in patients with cystic fibrosis.
Thorax,
November 1, 2006;
61(11):
962 - 966.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 American Thoracic Society
|
|
|